Review

Achieving control of asthma in preschoolers

Thomas Kovesi, Suzanne Schuh, Sheldon Spier, Denis Bérubé, Stuart Carr, Wade Watson and R. Andrew McIvor
CMAJ March 09, 2010 182 (4) E172-E183; DOI: https://doi.org/10.1503/cmaj.071638

The cases

Billy, who is 2 years old, presents to the physician’s office with his fourth episode of wheezing in the past 18 months. He was admitted to hospital at 6 months of age with bronchiolitis caused by respiratory syncytial virus. At 9 months, he was seen in the local emergency department with a cold complicated by wheezing and severe cough. He was discharged home with salbutamol, to be given by metered-dose inhaler and valved holding chamber, and a 7-day course of amoxicillin. He had a similar episode resulting in another emergency department visit 2 months later, and his community physician advised the family to administer beclomethasone–hydrofluoroalkane 100 μg twice daily for 2 weeks for subsequent upper respiratory tract infections. Despite these measures, Billy has had 4 more colds complicated by wheezing, cough and dyspnea. During 2 of these episodes, “bronchitis” was diagnosed, and he was given azithromycin. His wheezing typically improves for 2 hours after he receives salbutamol. Between colds, he has no symptoms. He has no other medical problems, and his growth is normal. Billy was born at term, but was small for his gestational age. His mother had smoked 10 cigarettes per day through the pregnancy. His parents have 3 questions: Does Billy have asthma? How can they help him to handle colds better? Will he outgrow this condition?

Chantal, who is 4 years old, first experienced wheezing in association with colds at 11 months of age. By 3 years of age, she had a nighttime cough even between colds and played for shorter periods than the other children in her preschool because sustained activity led to wheezing and dyspnea. Asthma was diagnosed, and fluticasone 125 μg twice daily by spacer was prescribed, along with salbutamol as needed. However, Chantal’s parents were worried about adverse effects and administered the medications only when she was especially unwell. During the past year, Chantal has visited the emergency department and received prednisone twice, but she has never been admitted to hospital. She has eczema, and both parents have hay fever. Her parents want to know whether it is safe to give her inhaled corticosteroids over a long period of time.

Asthma is the most common chronic disease among children, 1 affecting 10% to 15% of children. 2,3 Asthma is a major reason for pediatric admissions to hospital 3,4 and visits to the emergency department. 5 Inadequate control of asthma, as defined by previous Canadian Asthma Consensus Guidelines, 6 is present in 26% to 45% of children with asthma, 7,8 which suggests that previous guidelines have still not been fully incorporated into Canadian clinical practice. 9,10

Since publication of the 2003 version of the Canadian Pediatric Asthma Consensus Guidelines, 11 important new information has emerged from randomized controlled trials, particularly with regard to treatment with inhaled corticosteroids and use of add-on controller therapies. Further information has become available about the classification of asthma in preschool-aged children through large studies 12–14 and during the planning of a large randomized trial. 15 Diagnosis is more challenging in young children than in adults, because conventional pulmonary function testing is unavailable for young patients. Although the medications used to treat asthma in children are generally the same as those used for adults, there are important differences between children and adults in terms of types of asthma and symptom patterns. In addition, there appear to be differences in the most effective strategies for each group.

Several national and international asthma guidelines, including those of the Global Initiative for Asthma 16 and organizations in the United States, 17 the United Kingdom, 18 New Zealand 19 and Australia, 20 also discuss pediatric asthma and have been recently updated. Important similarities and differences between our recommendations and these guidelines from other countries will be highlighted in the text.

Sources of information

Literature searches were performed to retrieve relevant articles on randomized controlled trials of asthma therapy in children published since the 2003 Canadian Pediatric Asthma Consensus Guidelines (updated to December 2004). 11 We used a structured literature search, originally developed by the Cochrane Collaboration Airways Group, to search its asthma registry, and pairs of authors independently graded the suitability of each article, resolving areas of disagreement by discussion. The following search strategy was employed: (child* or paediat* or pediat* or infan* or toddler* or bab* or young* or preschool* or “pre school*” or pre-school* or newborn* or “new born*” or new-born* or neo-nat* or neonat*) and ((steroid* or corticosteroid* or glucocorticoid* or “adrenal cortex hormone*” or budesonide or Pulmicort or fluticasone or Flixotide or Flovent or ciclesonide or Alvesco or triamcinolone or Kenalog or beclomethasone or Becotide or flunisolide or Aerobid or Symbicort or Seretide) or (leukotriene* or leucotriene* or anti-leukotriene or anti-leucotriene or montelukast or Singulair or zafirlukast or Accolate)) (n = 436 records). In addition, we performed hand searches of journal articles identified by PubMed searches in the areas of intermittent asthma, persistent asthma in preschoolers and emergency treatment. In many of these topic areas, large, well-conducted randomized controlled trials are not available, but we included the best available articles.

We based our grades of evidence and levels of recommendations, determined by consensus, on those of the Canadian Task Force on Preventive Health Care, 21 as described previously. 22

Diagnosis and patterns of asthma

For children under 6 years of age, for whom conventional pulmonary function testing is not feasible, the diagnosis of asthma is based on a typical pattern of symptoms (cough with wheezing or dyspnea that typically varies in severity over time), response to therapy (either immediately after administration of a bronchodilator or, perhaps more importantly, over time after initiation of anti-inflammatory therapy) and absence of “warning signs” that suggest an alternative diagnosis (Table 1). 11 Primary care data suggest that asthma can be diagnosed accurately with basic clinical information in 85% of children. 23

View this table:

Table 1: Other diagnoses to consider in young children with asthma-like symptoms

Both parents and health care professionals may confuse wheezing with noisy breathing caused by retained upper airway secretions that the child has not learned to swallow or is unable to swallow; such noisy breathing is especially common in infants 24 and children with severe developmental delay. In patients with mild asthma-like symptoms, it may be challenging to differentiate cough or congestion typical of a viral cold from mild asthma; in such patients, a trial of therapy is often helpful. Excess production of mucus is a key component of airway obstruction in asthma. Plugging with mucus can cause crackles or radiographic evidence of atelectasis. In patients with viral respiratory tract infection and fever, these findings often lead to an incorrect diagnosis of “bronchitis” or pneumonia. The most common cause of recurrent “bronchitis” or pneumonia in children is underappreciated asthma, 25 which may be the underlying cause of “recurrent pneumonia” in up to 92% of pediatric cases. 26

Currently available asthma therapies are highly effective, and a lack of response to appropriately dosed therapy should prompt a search for suboptimal adherence to therapy, improper inhaler technique or a different diagnosis. 11 The Australian asthma guidelines stress the importance of ruling out other diagnoses when wet cough is the main symptom and when shortness of breath or wheezing is absent, particularly in indigenous children, 20 in whom other diagnoses, such as bronchiectasis, are relatively common. Bronchiectasis also appears to be more common among First Nations and Inuit Canadian children, particularly if there is a history of severe infection of the lower respiratory tract early in life. 27,28

Although the principles for diagnosing asthma have not changed since the previous guidelines, the importance of classifying preschool asthma on the basis of pattern of symptoms and association with atopy and outcome has become increasingly evident. About half of children never wheeze during the first 3 years of life. About 20% of children have early transient wheezing in the first 3 years of life, and 15% to 20% begin wheezing after 3 years of age. Another group of children (14%–16%) will have persistent wheezing that starts before the age of 3 years and is still present at age 6. 12,14 Large population-based studies have suggested that about two-thirds of children with wheezing in the first 3 years of life will no longer have wheezing by 6 years of age. 12 These data suggest 2 principal types of asthma in young children: early transient wheezing and persistent asthma. The Modified Asthma Predictive Index, 15 which has been validated in several independent populations, 13,29 may help to identify those young children at highest risk for persistent asthma (Box 1).

Figure

Box 1: Modified Asthma Predictive Index*†

Transient asthma induced by viral infections typically starts in the first 3 years of life. Children with this pattern usually have no symptoms between colds, do not have atopic disease (e.g., have no eczema or allergic rhinitis) and have no first-degree relatives with asthma. This type of asthma may be related to the presence of smaller-than-normal airways at birth, possibly associated with in utero exposure to maternal smoking. The symptoms often abate by 6 years of age with growth of the airways. 12 Although transient, intermittent asthma has traditionally been considered a mild condition, some children have severe episodes of intermittent asthma, precipitated by colds and resulting in multiple visits to the emergency department or admissions to hospital. 17 The risk factors for severe intermittent asthma, other than prior severe episodes, 30 have not been clearly identified, although one recent study indicated that some children with severe intermittent asthma may have atopic disease. 31

Chronic or persistent asthma may begin either before or after 3 years of age. Children with chronic asthma have exacerbations caused by colds, as well as by exposure to allergens or irritants. These children almost always exhibit symptoms between major exacerbations, such as nighttime cough or cough, wheeze or excessive dyspnea with exercise, with the symptoms fluctuating over time. They also tend to have allergies and other atopic diseases, such as eczema or allergic rhinitis, and often have a family history of atopy. These children are less likely to “outgrow” their asthma. 12

The recommendation to differentiate between transient and intermittent wheezing is also included in the British, 18 Australian 20 and New Zealand 19 asthma guidelines. The British guidelines suggest more detailed investigations and referral to a specialist for children who have symptoms but a low probability of asthma. 18 The latest US guidelines recognize that intermittent asthma is not necessarily mild. 17

Management of intermittent asthma

Although intermittent therapy with conventional doses of inhaled corticosteroids remains common practice in Canada, this practice was discouraged in the previous Canadian guidelines. 11 A more recent well-designed study has confirmed the ineffectiveness of the intermittent approach. 32 Novel studies have suggested that therapy with leukotriene receptor antagonists, administered regularly or intermittently, may be effective in children with intermittent asthma. 33,34

Bronchodilators

All children with asthma must have access to an inhaled rapid-acting bronchodilator, such as salbutamol. Their families must receive asthma education and a written action plan, and the child must have regular follow-up. Because coordination in children is poor, those using a metered-dose inhaler should use a valved holding chamber. By 5 or 6 years of age, many children can use a dry powder inhaler, which has the advantages of portability and lower cost (no need to purchase a holding chamber). Wet nebulizer therapy is rarely necessary. 11

Inhaled corticosteroids

Few studies have evaluated regular treatment with inhaled corticosteroids for children with intermittent asthma. One Cochrane review found no evidence to suggest that a low daily dose of inhaled corticosteroids was beneficial. 35 However, there were methodologic limitations in the 2 studies included in the review. 36,37 The 2003 Canadian Pediatric Asthma Consensus Guidelines specified, on the basis of expert consensus, that inhaled corticosteroids, administered regularly, were effective for children with intermittent asthma. 6,11 Since then, in a 2-year study of 285 toddlers at risk for asthma (on the basis of the Modified Asthma Predictive Index 15 [Box 1]), most of whom probably had intermittent asthma, regular therapy with fluticasone 100 μg twice daily improved asthma control but did not prevent the development of asthma, as determined during a subsequent year of observation. 38 An additional large study examining early introduction of fluticasone also showed that therapy did not alter prognosis. 39

Earlier studies examining the intermittent use of inhaled corticosteroids in children with intermittent asthma reported some improvements in symptoms, but not in the prevention of more severe exacerbations or progression to persistent asthma. 32,40,41 A Cochrane review published after the 2003 Canadian guidelines concluded that the available evidence was inconclusive with regard to parent-initiated oral corticosteroid therapy for the management of intermittent wheezing in children. 42

The guidelines of the Global Initiative for Asthma noted a continuing lack of high-level evidence demonstrating the clinical benefits of inhaled or systemic corticosteroids for intermittent viral-induced wheeze. 16 The US guidelines did not discuss intermittent use of inhaled corticosteroids, but recommended treating patients with intermittent asthma who are at high risk with continuous inhaled corticosteroids; 17 this would roughly correspond to our definition of children with severe episodes of intermittent asthma. The guidelines of the Global Initiative for Asthma also noted that inhaled corticosteroids do not induce remission of asthma and that symptoms generally return once treatment is stopped. 16 Similarly, the US guidelines noted that inhaled corticosteroids do not appear to alter outcome but are important for controlling symptoms. 17 Inhaled corticosteroids may be particularly helpful for children with recurrent wheezing and a positive Modified Asthma Predictive Index 15 (Box 1).

Leukotriene receptor antagonists

Several recent studies have examined the effectiveness of the leukotriene receptor antagonist montelukast in children with intermittent asthma. Regular therapy with montelukast for 12 months significantly reduced the rate of asthma exacerbations in preschool children with intermittent asthma. However, the treatment did not significantly reduce prednisone use 43 and hence the clinical relevance of the reduction in exacerbations was not clear. In a large novel study involving children 2 to 14 years of age with intermittent asthma, administering montelukast from the onset of upper respiratory tract infections for a minimum of 7 days significantly reduced unscheduled health care visits, daytime and nighttime symptoms, days off from school or child care, and parents’ time off from work, although there was no significant reduction in duration of episodes, use of prednisolone or admission to hospital. 33 A Canadian study evaluated administration of montelukast for 6 weeks in September and October, 34 when rates of asthma exacerbations peak in Canada (probably because older children return to school and there is rapid spread of respiratory viruses among students). 44 Montelukast added to usual therapy in children 2 to 14 years of age, about two-thirds of whom had previous prescriptions for inhaled corticosteroids, reduced the number of days with worse asthma symptoms by 53%. However, in preschool children, the effect was significant only among boys. 34

The use of montelukast by children with viral-associated wheezing was not discussed in the New Zealand asthma guidelines, 19 but was supported in the guidelines of the Global Initiative for Asthma. 16 The Australian 20 and British 18 guidelines discussed the use of sodium cromoglycate and nedocromil sodium in children with frequent, intermittent asthma. We do not discuss these agents, as nonsteroidal anti-inflammatory asthma medications other than montelukast are now used only infrequently in Canada.

Outcome of the first case (Billy)

Billy receives a diagnosis of severe intermittent asthma, which warrants regular controller therapy. Billy’s result on the Modified Asthma Predictive Index is negative, and the family is told that he has about a two-thirds chance of eventually “outgrowing” his asthma, probably by the time he reaches school age. Regular therapy with beclomethasone–hydrofluoroalkane 100 μg twice daily by valved holding chamber and salbutamol as needed are prescribed for Billy. Although Billy has 5 colds over the subsequent 5-month period, none result in asthma-related symptoms; his beclomethasone dose is therefore halved. Billy experiences no difficulties with colds for another 4 months, and the beclomethasone–hydrofluoroalkane is discontinued.

Management of persistent asthma

Since publication of the 2003 Canadian guidelines, newer, high-quality studies have reaffirmed the effectiveness of regular therapy with inhaled corticosteroids for young children with persistent asthma and have suggested a role for newer inhaled corticosteroids, which may also be even safer.

Environmental control

Given the close association of persistent asthma with atopy, management of persistent asthma in children should always start with environmental control, including, as for all children, avoidance of exposure to cigarette smoke. 6 Appropriate allergy skin testing will help to direct a patient-specific approach to environmental control. Control of asthma should be specifically assessed and documented during every clinical visit (Table 2). 6 The guidelines of the Global Initiative for Asthma also emphasized the importance of evaluating control and attempting to achieve excellent control (i.e., no symptoms or manifestations of disease). 16 A recent study suggested that parental reports may overestimate the degree of asthma control. 7 As such, the physician’s assessment may benefit from asking the child directly about symptoms, as well as specifically determining the occurrence of previous severe exacerbations.

View this table:

Table 2: Minimum criteria for acceptable control of asthma in preschoolers*

Inhaled corticosteroids

The most recent Canadian Pediatric Asthma Consensus Guidelines stated that inhaled corticosteroids are the anti-inflammatory drug of choice for persistent asthma. 11 Conventional doses of inhaled corticosteroids have an onset of action within 1–6 weeks, and regular therapy is therefore essential for therapeutic benefit. 45 Recent studies have continued to demonstrate the efficacy of inhaled corticosteroids for young children with chronic symptoms. Bisgaard and colleagues 46 found that fluticasone 100 μg, given twice daily to preschool children, reduced the frequency of mild or severe exacerbations (defined in terms of use of prednisone, visits to the emergency department and admission to hospital), symptoms and need for bronchodilators significantly more than use of inhaled sodium cromoglycate. In another recent study, fluticasone 100 μg twice daily reduced exacerbations by half, relative to placebo. 47 Ciclesonide, a new inhaled corticosteroid, given at doses of 100 or 200 μg once daily, significantly improved symptoms and pulmonary function and reduced bronchodilator use among children 4 years of age and older. 48 All currently available inhaled corticosteroids appear to have similar efficacy. Approximate dose equivalences are provided in Table 3. 45

View this table:

Table 3: Starting doses for inhaled corticosteroids for asthma therapy in children in Canada*

Studies of older individuals have shown that the common practice of doubling the dose of inhaled corticosteroid during exacerbations is ineffective, 49,50 and this is likely true for preschool children as well. During a severe exacerbation, the most effective therapy to prevent a visit to the emergency department 51 or admission to hospital 52 is a short course of prednisone (see the section “Emergency management of asthma: systemic cortiosteriods” in this article). With good control, severe exacerbations should be infrequent. 11

The main limitation of inhaled corticosteroids in clinical practice is concern about toxicity. Fortunately, the toxicity of low to moderate doses of inhaled corticosteroids (Table 3) 45 in young children appears minimal, although the data are somewhat contradictory. Nebulized budesonide at doses of up to 1000 μg daily for 12 weeks had no significant effect on adrenocorticotropic hormone stimulation tests in infants 6–12 months of age. 53 Fluticasone 100 μg twice daily for 12 weeks caused little change in urinary excretion of cortisol and no significant change in rate of linear growth. 54 Conversely, in a large recent study of children 2–3 years of age at risk for asthma, fluticasone 100 μg twice daily for 2 years significantly reduced the mean increase in height by 1.1 cm at 24 months, with some catch-up growth apparently occurring after cessation of the inhaled corticosteroids. 38 However, in school-aged children, ciclesonide 200 μg daily for 1 year had no effect on linear growth velocity. 55 Furthermore, ciclesonide 100 or 200 μg once daily had no effect on urinary cortisol or adrenocorticotropic hormone stimulation tests in children 4 years and older. 48

High doses of inhaled corticosteroid — particularly doses equivalent to more than 500 μg per day of fluticasone —have been associated with symptomatic adrenal suppression and hypoglycemia, as well as reduced growth velocity. 56 The growth of children who are receiving inhaled corticosteroids should be monitored at every clinical visit. For this purpose, a pediatric growth chart should be used (e.g., growth charts of the Centers for Disease Control and Prevention, available at www.cdc.gov/nchs/about/major/nhanes/growthcharts/charts.htm). Re-evaluation of the dose of inhaled corticosteroid or addition of a second controller agent (see “Augmentation and add-on therapies,” below), or both, should be considered if growth is 1–2 cm less than expected per year 57,58 or if growth drops by more than a major percentile on the growth chart. Children who are receiving high doses of inhaled corticosteroids should be referred to an asthma specialist, and consideration should be given to monitoring adrenal function by measuring the fasting morning serum cortisol level. The Australian asthma guidelines noted that the administration of inhaled corticosteroids at or above 200 μg of beclomethasone–hydrofluoroalkane daily or equivalent (i.e., equivalent to 200 μg of fluticasone) “may be associated with systemic side-effects.” 20

Starting doses of inhaled corticosteroids are similar to initial doses for older children and adults (Table 3). The dose need not be scaled down because of body size. 6 The Australian asthma guidelines did not specify dosing for inhaled corticosteroids in pediatric asthma. 20 The guidelines of the Global Initiative for Asthma stated that daily doses of budesonide 400 μg (or equivalent) or less result in near-maximal benefits for most patients 5 years of age and younger. 16 Once good asthma control has been achieved (Table 2), it is reasonable to reduce the dose of inhaled corticosteroid by about 50% at each follow-up visit; such visits are ideally scheduled every 2–3 months, with the child likely to have had further exposure to triggers in the periods between appointments. 11 If control worsens, the previous dose should be resumed. If control is maintained, further reductions in dose can be recommended. If no symptoms occur after 3–6 months of therapy with low doses of inhaled corticosteroids, the physician may consider attempting to stop the medication. 11

Leukotriene receptor antagonists

Older data indicated that the leukotriene receptor antagonist montelukast, at a dose of 4 mg daily, significantly reduced daytime symptoms, nighttime cough, need for β2-agonist rescue therapy and need for oral corticosteroids among children 2–5 years of age. 59 A recent small study involving toddlers 10 to 26 months of age also found that montelukast significantly improved lung function, airway inflammation (as measured by exhaled nitric oxide) and symptom scores. 60 This medication has the advantages of oral administration and rapid action, with 1-day onset of action and establishment of maximal effect in 3 weeks, as well as a low risk of adverse effects. Recent studies have suggested that in older children with persistent asthma, inhaled corticosteroids are more effective than leukotriene receptor antagonists. 61,62 If control with leukotriene receptor antagonists is inadequate, an inhaled corticosteroid should probably be substituted or added in younger children as well. In a recent study of somewhat older children (6–17 years of age), more patients responded to fluticasone than to montelukast, although a substantial minority responded to both; the response to fluticasone was particularly likely among children with stronger evidence of atopy. 63

Recent asthma guidelines from the United Kingdom noted strong evidence to support the use of leukotriene receptor antagonists for children under 5 years of age. 18 The US guidelines also stated that there is evidence to support the use of montelukast or sodium cromoglycate in children under 5 years of age, noting that either of these drugs could be used if an inhaled corticosteroid, the drug of choice, cannot be prescribed or is refused by the family. 17

The second case continued (Chantal)

Chantal’s family agrees to have her continue taking fluticasone 125 μg twice daily on a long-term basis, and they appreciate the improvement in control of her asthma. Unfortunately, after her grandmother moves to a residence for seniors, the family agrees to look after her dog, even though skin prick tests have indicated that Chantal is allergic to cats and dogs. Chantal begins awakening with nighttime cough about 3 nights per week and has to drop her preschool gymnastics program because of dyspnea on exertion.

Augmentation and add-on therapies

Unfortunately, since publication of the most recent pediatric guidelines, no high-quality data on the role of long-acting β2-agonists in pediatric asthma have been published. One large study, which probably included few preschool children, focused on strategies for the use of combination inhalers with long-acting β2-agonist and inhaled corticosteroid, rather than on the efficacy of the long-acting bronchodilator component. 64

When asthma control remains poor despite a low or moderate dose of inhaled corticosteroids, the first step is to assess compliance, given that families often stop maintenance therapy between asthma exacerbations. 34,65 The physician should also look for comorbidities such as allergic rhinitis or sinusitis and should consider the possibility of new exposure or sensitization to allergens. 6 If there are no such confounding factors, the dose of inhaled corticosteroid should be increased or a second controller medication added: either a leukotriene receptor antagonist or a long-acting β2-agonist. 6 For preschool children, older research indicated that the therapeutic benefits of leukotriene receptor antagonist monotherapy, such as a reduction in symptoms and in the need for rescue therapy with oral steroids, also occur when a leukotriene receptor antagonist is added to an inhaled corticosteroid. 59

Long-acting β2-agonists

The long-acting β2-agonist salmeterol is approved in Canada as an add-on agent to inhaled corticosteroids in children 4 years of age or older. However, very few published studies have examined long-acting β2-agonists in prepubertal children, and all published pediatric studies have included children 7 years of age and older. These data are equivocal about the benefits of adding a long-acting β2-agonist, and a systematic review found no evidence that adding a long-acting β2-agonist to inhaled corticosteroids reduced exacerbations in children. 66 In one study of children 4 to 11 years of age, budesonide and formoterol improved pulmonary function more than budesonide alone, although both treatments had similar effects on other asthma outcomes. 67 Among children 7 to 11 years of age, adding montelukast to budesonide reduced airway inflammation, as assessed by measurement of exhaled nitric oxide, more than adding formoterol did. 68

A large study examined the use of a combination inhaler containing the inhaled corticosteroid budesonide and the rapid-acting, long-acting β2-agonist formoterol, for children as young as 4 years of age. 64 The patients were randomly assigned to receive a fixed dose of the combination inhaler for maintenance therapy plus a short-acting reliever, maintenance therapy with the combination inhaler plus additional doses of the combination inhaler for relief, or a higher dose of inhaled corticosteroid alone plus a short-acting reliever. Using the combination inhaler for regular maintenance and relief reduced the likelihood of exacerbations. Thus, using this inhaler in this fashion may improve outcomes in children.

Given the dearth of studies of long-acting β2-agonists in the preschool age group, these medications should probably be reserved for patients with more severe disease, such as those whose asthma is unresponsive to high doses of inhaled corticosteroids (Table 3) or moderate or high doses of inhaled corticosteroids and a leukotriene receptor antagonist. Careful monitoring of response and adverse effects is required for children who are treated with long-acting β2-agonists.

The approach we recommend for the treatment of persistent asthma is similar to that recommended in the New Zealand guidelines 19 and the guidelines of the Global Initiative for Asthma. 16 The British guidelines 18 provided no criteria for introducing add-on therapy for children below 5 years of age, recommended a leukotriene receptor antagonist for add-on therapy for children 2 to 5 years of age and recommended a long-acting β2-agonist for children 5 to 12 years of age. For children under 2 years of age needing add-on therapy and for children 2 to 5 years of age with no response to the combination of leukotriene receptor antagonist and inhaled corticosteroid, the British guidelines recommended referral to a specialist. 18 The Australian guidelines indicated that leukotriene receptor antagonists “can be used as sole therapy in children with frequent intermittent or mild persistent asthma.”20 These guidelines also noted, as we do, the lack of evidence supporting the use of long-acting β2-agonists in children. Both the Australian 20 and British 18 asthma guidelines mentioned theophylline, which we do not discuss because of its infrequent use in children in Canada and the relatively high incidence of adverse effects. The US guidelines 17 suggested that for children with inadequate control of asthma with moderate doses of inhaled corticosteroid, the dose of inhaled corticosteroid should be increased before a second-line agent is added, either a leukotriene receptor antagonist or long-acting β2-agonist. Those guidelines also stated that there is inadequate evidence to make good recommendations for children below 5 years of age. For school-aged children, a long-acting β2-agonist was recommended for add-on therapy (based on extrapolation of data for adolescents). 17

Monoclonal anti-immunoglobulin E antibody

Omalizumab is a novel monoclonal anti-immunoglobulin E antibody administered every 2 to 4 weeks by subcutaneous injection. For children 6 years of age or older with moderate to severe allergic asthma and serum immunoglobulin E in a relatively narrow range of 70 to 1700 μg/L (30 to 700 IU/mL), this drug is associated with significant improvements in asthma outcomes, including rates of exacerbations. 69 Omalizumab has not yet been studied in the preschool age group and is licensed in Canada for children 12 years of age and older. The drug is costly and is probably best reserved currently for adolescent patients with very severe allergic asthma. 70

Emergency management of asthma

The second case continued (Chantal)

Chantal’s family reads on the Internet that inhaled corticosteroids are “addictive” and decide to stop the child’s fluticasone. The next month, while Chantal has a cold, the family visits her aunt, who has 5 cats. Chantal experiences severe dyspnea and wheezing. She is given salbutamol 200 μg every 4 hours, but her condition does not improve, and she is taken to the local emergency department. She is alert and afebrile. Her oxygen saturation is 92% and her respiratory rate 56 breaths per minute. There is an obvious tracheal tug and intercostal retractions, and her air entry is slightly reduced, with biphasic wheezing.

Initial management in the emergency department

Recent studies of management of asthma in the emergency department have focused on objective assessment of the severity of asthma and rapid provision of effective treatment. Care is guided by the clinical evaluation, including a directed history and a physical examination focused on key warning signs of rapid deterioration (Box 2) or severe exacerbation (Box 3) and measurement of oxygen saturation by pulse oximetry. The history should reveal whether inhaled corticosteroids are being used regularly or only during exacerbations. The Preschool Respiratory Assessment Measure 71 (PRAM) has been validated as a responsive index of asthma severity 72 and is being incorporated into clinical pathways of the emergency departments in several Canadian hospitals (Appendix 1, available at www.cmaj.ca/cgi/content/full/cmaj.071638/DC1).

Figure

Box 2: Key historical and clinical red flags indicating rapid deterioration or severe exacerbation

Figure

Box 3: Physical findings suggestive of severe exacerbation 16

Chest radiography is appropriate only if the child is severely ill, particularly if another or concurrent diagnosis is strongly suspected, such as pneumonia, lobar atelectasis, pneumomediastinum or pneumothorax. 73

Oxygen therapy

Supplemental oxygen therapy should be provided, when necessary, to raise oxygen saturation above 90%. 74 Arterial partial pressure of carbon dioxide (P CO2) should be estimated using arterial or arterialized capillary blood samples for children with no response to aggressive treatment, those with an abnormal level of consciousness and those who are in extreme respiratory distress. A recent study reported the estimation of carbon dioxide with an end-tidal carbon dioxide monitor; 75 however, this technique may be less accurate for patients with ventilation–perfusion inequality, as in those with acute asthma. 76 Most children with acute asthma have a low blood P CO2, so a “normal” value of P CO2 indicates a severe exacerbation.

Bronchodilators

Numerous randomized controlled trials and a recent systematic review 77 have revealed that administration of bronchodilators by metered-dose inhaler and valved holding chamber has efficacy similar to or greater than that achieved with administration by wet nebulizer in the prevention of hospital admission for children below 5 years of age. 78,79 Avoiding nebulizers may also help to prevent nosocomial viral infections. Patients (or their parents) should be told to bring their own holding chamber on subsequent visits to the emergency department to allow assessment of the patient’s technique and the condition of the device.

Young children have smaller airways and breathe more through the nose than is the case for older children and adults, and deposition of bronchodilators in the lower airways is therefore less, regardless of the device. As such, relatively large doses of β2-agonists are needed. 80,81 The salbutamol dose range for use with a metered-dose inhaler and valved holding chamber in the emergency department is 400 to 800 μg (4 to 8 puffs) per dose or about 0.3 puffs per kilogram body weight, to a maximum of 8 puffs. 82 Each puff should be administered separately, to avoid sedimentation of the inhaled particles in the valved holding chamber. Nebulizers are much less efficient, and the comparable dose is 2.5 mg for children weighing less than 15 kg and 5 mg for heavier children. 83 These doses should be given every 20 minutes or more to more severely ill children and hourly to patients with less severe disease until the child’s respiratory distress declines. 84

In contrast, the New Zealand guidelines recommend salbutamol at doses of 6 puffs for children less than 5 years of age and 12 puffs for children 5 years and older, 19 and the Australian guidelines suggest 4 to 6 inhalations for children below 6 years of age and 8 to 12 puffs for those over 6 years of age. 20 The British guidelines recommend 2 to 4 puffs repeated every 20 to 30 minutes for children over 2 years of age who are having mild exacerbations and up to 10 puffs for children experiencing severe exacerbations. 18 The US guidelines recommend therapy either by wet nebulizer or by metered-dose inhaler and spacer. 17

Although continuous treatment with inhaled salbutamol has been shown to reduce rates of admission to hospital for adults, 85 only one pediatric study has been published. 86 It is difficult to draw meaningful conclusions from this report because of methodologic limitations. The most important adverse effects of β2-agonists include hyperactivity, tremor, tachycardia and mild hypokalemia. 84 These rarely limit therapy, but potassium supplementation may be necessary for children who receive extended bronchodilator therapy in the emergency department or for those who are admitted to hospital or are receiving diuretics. After discharge, the usual dose of salbutamol is 2 puffs (200 μg) every 4 hours, which the family should wean to every 4 hours as needed, as symptoms subside. The caregivers should be instructed to return to the emergency department if bronchodilators are needed more often than every 4 hours.

For children with severe disease, adding 3 consecutive doses of ipratropium to salbutamol therapy improves lung function and decreases rates of admission to hospital. 87–89 Adverse effects are rare. 88 Although the optimal dose is unknown, 4 puffs (80 μg) by metered-dose inhaler and valved holding chamber 90 or 250 μg by nebulizer has been shown to be effective. 82,88

Systemic corticosteroids

Systemic corticosteroids lessen symptoms and airway obstruction, improve oxygenation and decrease the likelihood of admission to hospital from the emergency department. 52 These drugs should therefore be considered part of the initial treatment for all but the mildest asthma exacerbations. 91 Intravenous therapy is indicated only for children with persistent vomiting or very severe disease (score of 8 or more on Preschool Respiratory Assessment Measure [see the section “Initial management in the emergency department” in this article]). Because it takes several hours for the anti-inflammatory action of corticosteroids to take effect, these drugs should be started as soon as possible after the child’s arrival in the emergency department. The recommended dose of oral prednisolone or prednisone is 1–2 mg/kg (maximum 60 mg/dose) given daily for 5 to 7 days. 52 Tapering is not necessary for short (even 10-day) courses of therapy. 92 Dexamethasone syrup has a longer physiologic half-life than prednisone, and a 2-day course of this medication, at a dose of 0.15 mg/kg, 93 may therefore be just as effective as 5 days of treatment with prednisone. In patients with mild to moderate exacerbations, a single dose of dexamethasone of 0.6 mg/kg may be similarly effective. 94 Both older and more recent studies have indicated that inhaled corticosteroids are less effective than oral corticosteroids during acute exacerbations in children, 95,96 and systemic corticosteroids should therefore be used for stabilization. 97

Additional therapies

Additional therapies are available for severely ill children with no response to standard treatment. Magnesium relaxes smooth-muscle cells, 98 may reduce neutrophilic inflammation 99 and is useful in the treatment of refractory, severe acute asthma in children. Both randomized placebo-controlled trials 100,101 and a recent systematic review 102 reported that this agent reduces the need for admission to hospital and improves lung function in children with severe acute asthma. Magnesium is given intravenously over 30 minutes. Although the optimal dose is unknown, the most appropriate dosing appears to be 25–75 mg/kg per dose. The clinical response usually occurs within minutes. Given the short half-life of this drug, some patients require repeated infusions. Although it is generally very safe, rare cases of hypotension have occurred. The Global Initiative for Asthma guidelines took a cautious approach and underlined the fact that the infusion of magnesium has not been studied in young children. 16 The use of magnesium by inhalation remains investigational. 103

New evidence suggests that a helium–oxygen mixture may be beneficial for patients with severe disease, 104 and it can also be used to drive wet nebulizers. 105 It is usually prepared as a mixture of 80% helium and 20% oxygen, although other ratios are also possible. Because the density of helium is about one-third that of air, airway resistance in the presence of turbulent airflow is reduced. Helium–oxygen may be of benefit to patients with severe disease. 104 In one recent study, using helium–oxygen, rather than oxygen, to drive wet nebulizers during continuous salbutamol therapy resulted in greater improvement in respiratory status. 106 This gas mixture may be considered for patients with severe exacerbations poorly responsive to other treatments in centres experienced in its use. Patients requiring therapy with either helium–oxygen or magnesium must be admitted to hospital.

Depending on the severity of the exacerbation, admission to a hospital providing specialized pediatric care or an intensive care unit may be required. Several factors can be used to determine the need for admission (Box 4).

Figure

Box 4: Guidelines for admitting children with asthma to hospital 16

Discharge planning

The families of patients being discharged from the emergency deparment should receive, before discharge, education about the therapeutic plan and correct use of the inhaler device. Information on indications that should prompt return to the emergency department and a written action plan should also be provided. 107 One recent study suggested that a single follow-up visit, occurring in the emergency department, for children with a recent visit to the emergency department or admission to hospital may reduce subsequent unscheduled health care visits. 108 Follow-up with a primary care physician within several days is advisable, and the primary care physician or an asthma specialist (see below) should plan to reassess the level of control and the dose of maintenance therapy about 4 to 8 weeks later.

To prevent further exacerbations, the patient should receive a course of oral corticosteroids (as described above), and regular treatment with inhaled corticosteroids should be either introduced or emphasized (if the patient is not already taking such drugs or they are being used irregularly). If the patient is already receiving regular treatment with inhaled corticosteroids, the maintenance treatment regimen should be reviewed and optimized, as described above.

The indications for referral to a pediatric asthma specialist include recurrent visits to the emergency department or admissions to hospital for asthma within the past year, any admission to an intensive care unit for asthma, recurrent exacerbations or poor control despite attempts by the community physician to optimize therapy, poor adherence with asthma therapy or evidence of inadequate understanding of the therapeutic regimen. In many communities, asthma education programs are available. Such programs offer more intense education and can enhance adherence.

Our suggested management of acute asthma is generally similar to that recommended by the Global Initiative for Asthma 16 and the Australian 20 and New Zealand 19 guidelines.

Outcome of the second case (Chantal)

Prednisone is started for Chantal, and she and her family spend 5 hours in the emergency department, during which time salbutamol is given by valved holding chamber every 2 hours. Chantal is then sent home on a 5-day course of prednisone. She is referred to a community asthma education program, where her parents receive detailed information on inhaler technique and the risks and benefits of inhaled corticosteroids. Although they were impressed by the severity of Chantal’s exacerbation, the parents cannot be convinced to relocate the family’s dog. Fortunately, they do agree to resume regular therapy with inhaled corticosteroids.

Gaps in knowledge

The key messages for the management of asthma in children are presented in Box 5.

Figure

Box 5: Key messages for achieving control of asthma in preschoolers

More data are urgently needed to evaluate the efficacy of regular therapy with inhaled corticosteroids in young children who have only intermittent asthma. More research is also required to define the effectiveness of long-acting β2-agonists in young children and to compare different strategies for the use of long-acting combination inhaler therapy with β2-agonist and inhaled corticosteroid. Additional work verifying the efficacy of intermittent therapy with leukotriene receptor antagonists would also be valuable. The key messages presented here do not identify potential differences in the presentation and outcome of asthma that may occur among First Nations and Inuit children, an issue that has already been discussed in the New Zealand guidelines. 19 The British guidelines also discuss other ethnic subgroups who may be at particular risk for increased morbidity and mortality related to asthma. 18

    Key points

  • A child’s pattern of asthma may help to predict whether the child will “outgrow” the condition.

  • Inhaled steroids are the controller medication of choice for children.

  • To be effective, inhaled steroids must be given regularly, for at least a season at a time, not just during asthma attacks.

  • Leukotriene receptor antagonists may be useful for asthma triggered by colds.

  • Most children who are seen in the emergency department can be given bronchodilator therapy with a metered-dose inhaler and valved spacer.

Articles to date in this series

  • Subbarao P, Mandhane PJ, Sears MR. Asthma: epidemiology, etiology and risk factors. CMAJ 2009. DOI:10.1503/cmaj.080612.

  • Kaplan AG, Balter MS, Bell AD, et al. Diagnosis of asthma in adults. CMAJ 2009. DOI:10.1503/cmaj.080006.

  • Balter MS, Bell AD, Kaplan AG, et al. Management of asthma in adults. CMAJ 2009. DOI:10.1503/cmaj.080007.

  • Chapman KR, McIvor RA. Asthma unresponsive to usual care. CMAJ 2009. DOI:10.1503/cmaj.090089.

  • Hodder R, Lougheed MD, Rowe BH, et al. Management of acute asthma in adults in the emergency department: nonventilatory management. CMAJ 2009. DOI:10.1503/cmaj.080072.

  • Hodder R, Lougheed MD, Rowe BH, et al. Management of acute asthma in adults in the emergency department: assisted ventilation. CMAJ 2009. DOI:10.1503/cmaj.080073.

Footnotes

  • Previously published at cmaj.ca

    This article has been peer reviewed.

    Competing interests: Thomas Kovesi has received honoraria and/or educational grants from AstraZeneca Canada, Nycomed Canada and Merck Frosst Canada. Suzanne Schuh has received funding from Boehringer-Ingelheim, GlaxoSmithKline and the Canadian Institutes of Health Research for investigator-initiated studies. Sheldon Spier has received speaker fees from Merck Frosst, AstraZeneca, Graceway and Nycomed. He has also served as a consultant on national advisory boards for Merck Frosst, AstraZeneca, Graceway and Nycomed. Denis Bérubé has had paid consultancies related to advisory boards with and has received speaker fees and/or educational grants from GlaxoSmithKline, Graceway Pharma, Merck Frosst, Nycomed and Novartis. Stuart Carr has served on an advisory board for Graceway Pharmaceuticals and with speakers’ bureaus for Graceway Pharmaceuticals, Merck Frosst Canada, Nycomed and Novartis. Wade Watson has served on advisory boards for GlaxoSmithKline and Nycomed. He has also received honoraria for continuing medical education from GlaxoSmithKline, Merck Frosst Canada, AstraZeneca, Nycomed and King Pharma. Andrew McIvor has attended advisory board meetings and provided continuing medical education for which he has received honoraria from pharmaceutical companies involved in asthma management: AstraZeneca, Borhringer-Ingelheim, Graceway, GlaxoSmithKline, Novartis, Merck Frosst and Pfizer.

    Contributors: All authors contributed to developing and drafting the article and revising it critically for important intellectual content, and all gave final approval of the version to be published.

    Funding: The Canadian Thoracic Society has received funding to facilitate the knowledge translation activities of the CTS Asthma Committee from AstraZeneca Canada, GlaxoSmithKline Inc., Merck Frosst Canada and Novartis Pharmaceuticals. None of the sponsors played a role in the collection, review, analysis or interpretation of the scientific literature or in any decisions regarding the key messages presented in the case studies.

    This article is the last in a 7-part case study series that was developed as a knowledge translation initiative of the Canadian Thoracic Society Asthma Committee. The series aims to educate and inform primary care providers and nonrespiratory specialists about the diagnosis and management of asthma. The key messages presented in the cases are not clinical practice guidelines but are based on a review of the most recent scientific evidence available. Financial support for the publication of this series has been provided, in part, by the Canadian Thoracic Society.

REFERENCES

  1. 1.↵
    Martin E. The CGHA asthma management program and its effect upon pediatric asthma admission rates. Clin Pediatr (Phila) 2001;40:425–34.
  2. 2.↵
    Kozyrskyj AL, Hildes-Ripstein GE. Assessing health status in Manitoba children: acute and chronic conditions. Can J Public Health 2002;93(Suppl 2):S44–9.
    OpenUrlPubMed
  3. 3.↵
    Life and breath: respiratory disease in Canada. Ottawa (ON): Public Health Agency of Canada; 2007. Available: www.phac-aspc.gc.ca/publicat/2007/lbrdc-vsmrc/index-eng.php (accessed 2009 Sep. 14).
  4. 4.↵
    Castro-Rodriguez JA, Holberg CJ, Wright AL, et al. A clinical index to define risk of asthma in young children with recurrent wheezing. Am J Respir Crit Care Med 2000;162:1403–6.
    OpenUrlCrossRefPubMed
  5. 5.↵
    Lougheed MD, Garvey N, Chapman KR, et al. The Ontario Asthma Regional Variation Study: emergency department visit rates and the relation to hospitalization rates. Chest 2006;129:909–17.
    OpenUrlCrossRefPubMed
  6. 6.↵
    Becker A, Lemière C, Bérubé D, et al. Summary of recommendations from the Canadian Asthma Consensus Guidelines, 2003. CMAJ 2005;173(Suppl 6):S3–11.
    OpenUrlFREE Full Text
  7. 7.↵
    Dell SD, Foty R, Becker A, et al. Parent-reported symptoms may not be adequate to define asthma control in children. Pediatr Pulmonol 2007;42:1117–24.
    OpenUrlCrossRefPubMed
  8. 8.↵
    Mo F, Robinson C, Choi BC, et al. Analysis of prevalence, triggers, risk factors and the related socio-economic effects of childhood asthma in the Student Lung Health Survey (SLHS) database, Canada 1996. Int J Adolesc Med Health 2003;15:349–58.
    OpenUrlPubMed
  9. 9.↵
    Klomp H, Lawson JA, Cockcroft DW, et al. Examining asthma quality of care using a population-based approach. CMAJ 2008;178:1013–21.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    Chapman KR. Asthma in Canada: missing the treatment targets. CMAJ 2008;178:1027–8.
    OpenUrlFREE Full Text
  11. 11.↵
    Becker A, Bérubé D, Chad Z, et al. Canadian Pediatric Asthma Consensus Guidelines, 2003 (updated to December 2004): introduction. CMAJ 2005;173 (6 Suppl):S12–4.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    Martinez FD, Wright AL, Taussig LM, et al. Asthma and wheezing in the first six years of life. The Group Health Medical Associates. N Engl J Med 1995;332:133–8.
    OpenUrlCrossRefPubMed
  13. 13.↵
    Moeller A, Diefenbacher C, Lehmann A, et al. Exhaled nitric oxide distinguishes between subgroups of preschool children with respiratory symptoms. J Allergy Clin Immunol 2008;121:705–9.
    OpenUrlCrossRefPubMed
  14. 14.↵
    Lowe LA, Simpson A, Woodcock A, et al. Wheeze phenotypes and lung function in preschool children. Am J Respir Crit Care Med 2005;171:231–7.
    OpenUrlCrossRefPubMed
  15. 15.↵
    Guilbert TW, Morgan WJ, Zeiger RS, et al. Atopic characteristics of children with recurrent wheezing at high risk for the development of childhood asthma. J Allergy Clin Immunol 2004;114:1282–7.
    OpenUrlCrossRefPubMed
  16. 16.↵
    Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008;31:143–78.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma US Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute; 2007. Available: www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (accessed 2009 Aug. 24).
  18. 18.↵
    British Thoracic Society; Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Thorax 2008;63 Suppl 4:iv1–121.
  19. 19.↵
    Paediatric Society of New Zealand. Management of asthma in children aged 1–15 years. Wellington (New Zealand): The Society; 2005. Available: www.nzgg.org.nz/guidelines/0104/Asthma_endorsed.pdf (accessed 2009 Sep. 28).
  20. 20.↵
    Beilby J, Berkelmans A, Brown C, et al. Asthma management handbook 2006. South Melbourne (Australia): National Asthma Council Australia; 2006. Available: www.nationalasthma.org.au/cms/index.php (accessed 2009 Aug. 24).
  21. 21.↵
    Canadian Task Force on Preventive Health Care. New grades for recommendations from the Canadian Task Froce on Preventive Health Care. CMAJ 2003;169: 207–8.
    OpenUrlFREE Full Text
  22. 22.↵
    Kaplan A, Balter M, Bell A, et al. Diagnosis of asthma in adults. CMAJ 2009. DOI:10.1503/cmaj.080006.
  23. 23.↵
    To T, Dell S, Dick PT, et al. Case verification of children with asthma in Ontario. Pediatr Allergy Immunol 2006;17:69–76.
    OpenUrlCrossRefPubMed
  24. 24.↵
    Elphick HE, Sherlock P, Foxall G, et al. Survey of respiratory sounds in infants. Arch Dis Child 2001;84:35–9.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    Taussig LM, Smith SM, Blumenfeld R. Chronic bronchitis in childhood: what is it?Pediatrics 1981;67:1–5.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    Eigen H, Laughlin JJ, Homrighausen J. Recurrent pneumonia in children and its relationship to bronchial hyperreactivity. Pediatrics 1982;70:698–704.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    Herbert FA, Wilkinson D, Burchak E, et al. Adenovirus type 3 pneumonia causing lung damage in childhood. CMAJ 1977;116:274–6.
    OpenUrlAbstract
  28. 28.↵
    Singleton R, Morris A, Redding G, et al. Bronchiectasis in Alaska Native children: causes and clinical courses. Pediatr Pulmonol 2000;29:182–7.
    OpenUrlCrossRefPubMed
  29. 29.↵
    Jang JY, Kim HB, Lee SY, et al. Asthma predictive index in children with recurrent wheezing. Korean J Pediatr 2006;49:298–304.
    OpenUrl
  30. 30.↵
    Federico MJ, Wamboldt FS, Carter R, et al. History of serious asthma exacerbations should be included in guidelines of asthma severity. J Allergy Clin Immunol 2007;119:50–6.
    OpenUrlCrossRefPubMed
  31. 31.↵
    Bacharier LB, Phillips BR, Bloomberg GR, et al. Severe intermittent wheezing in preschool children: a distinct phenotype. J Allergy Clin Immunol 2007;119:604–10.
    OpenUrlCrossRefPubMed
  32. 32.↵
    Bisgaard H, Hermansen MN, Loland L, et al. Intermittent inhaled corticosteroids in infants with episodic wheezing. N Engl J Med 2006;354:1998–2005.
    OpenUrlCrossRefPubMed
  33. 33.↵
    Robertson CF, Price D, Henry R, et al. Short-course montelukast for intermittent asthma in children: a randomized controlled trial. Am J Respir Crit Care Med 2007; 175:323–9.
    OpenUrlCrossRefPubMed
  34. 34.↵
    Johnston NW, Mandhane PJ, Dai J, et al. Attenuation of the September epidemic of asthma exacerbations in children: a randomized, controlled trial of montelukast added to usual therapy. Pediatrics 2007;120:e702–12.
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    McKean M, Ducharme F. Inhaled steroids for episodic viral wheeze of childhood. Cochrane Database Syst Rev 2000;(2):CD001107.
  36. 36.↵
    Doull IJ, Lampe FC, Smith S, et al. Effect of inhaled corticosteroids on episodes of wheezing associated with viral infection in school age children: randomised double blind placebo controlled trial. BMJ 1997;315:858–62.
    OpenUrlAbstract/FREE Full Text
  37. 37.↵
    Wilson N, Sloper K, Silverman M. Effect of continuous treatment with topical corticosteroid on episodic viral wheeze in preschool children. Arch Dis Child 1995; 72:317–20.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    Guilbert TW, Morgan WJ, Zeiger RS, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med 2006;354:1985–97.
    OpenUrlCrossRefPubMed
  39. 39.↵
    Murray CS, Woodcock AA, Langley S, et al. Secondary prevention of asthma by the use of Inhaled Fluticasone propionate in Wheezy INfants (IFWIN): double-blind, randomised, controlled study. Lancet 2006;368:754–62.
    OpenUrlCrossRefPubMed
  40. 40.↵
    Wilson NM, Silverman M. Treatment of acute, episodic asthma in preschool children using intermittent high dose inhaled steroids at home. Arch Dis Child 1990;65:407–10.
    OpenUrlAbstract/FREE Full Text
  41. 41.↵
    Connett G, Lenney W. Prevention of viral induced asthma attacks using inhaled budesonide. Arch Dis Child 1993;68:85–7.
    OpenUrlAbstract/FREE Full Text
  42. 42.↵
    Vuillermin P, South M, Robertson C. Parent-initiated oral corticosteroid therapy for intermittent wheezing illnesses in children. Cochrane Database Syst Rev 2006;(3):CD005311.
  43. 43.↵
    Bisgaard H, Zielen S, Garcia-Garcia ML, et al. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am J Respir Crit Care Med 2005;171:315–22.
    OpenUrlCrossRefPubMed
  44. 44.↵
    Johnston NW, Johnston SL, Duncan JM, et al. The September epidemic of asthma exacerbations in children: a search for etiology. J Allergy Clin Immunol 2005; 115:132–8.
    OpenUrlCrossRefPubMed
  45. 45.↵
    Boulet LP, Becker A, Bérubé D, et al. Canadian asthma consensus report, 1999. Canadian Asthma Consensus Group. CMAJ 1999;161(Suppl 11):S1–61.
    OpenUrlFREE Full Text
  46. 46.↵
    Bisgaard H, Allen D, Milanowski J, et al. Twelve-month safety and efficacy of inhaled fluticasone propionate in children aged 1 to 3 years with recurrent wheezing. Pediatrics 2004;113:e87–94.
    OpenUrlAbstract/FREE Full Text
  47. 47.↵
    Wasserman RL, Baker JW, Kim KT, et al. Efficacy and safety of inhaled fluticasone propionate chlorofluorocarbon in 2- to 4-year-old patients with asthma: results of a double-blind, placebo-controlled study. Ann Allergy Asthma Immunol 2006;96:808–18.
    OpenUrlPubMed
  48. 48.↵
    Gelfand EW, Georgitis JW, Noonan M, et al. Once-daily ciclesonide in children: efficacy and safety in asthma. J Pediatr 2006;148:377–83.
    OpenUrlCrossRefPubMed
  49. 49.↵
    Garrett J, Williams S, Wong C, et al. Treatment of acute asthmatic exacerbations with an increased dose of inhaled steroid. Arch Dis Child 1998;79:12–7.
    OpenUrlAbstract/FREE Full Text
  50. 50.↵
    FitzGerald JM, Becker A, Sears MR, et al. Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations. Thorax 2004;59:550–6.
    OpenUrlAbstract/FREE Full Text
  51. 51.↵
    Harris JB, Weinberger MM, Nassif E, et al. Early intervention with short courses of prednisone to prevent progression of asthma in ambulatory patients incompletely responsive to bronchodilators. J Pediatr 1987;110:627–33.
    OpenUrlCrossRefPubMed
  52. 52.↵
    Scarfone RJ, Fuchs SM, Nager AL, et al. Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma. Pediatrics 1993;92:513–8.
    OpenUrlAbstract/FREE Full Text
  53. 53.↵
    Berger WE, Qaqundah PY, Blake K, et al. Safety of budesonide inhalation suspension in infants aged six to twelve months with mild to moderate persistent asthma or recurrent wheeze. J Pediatr 2005;146:91–5.
    OpenUrlCrossRefPubMed
  54. 54.↵
    Qaqundah PY, Sugerman RW, Ceruti E, et al. Efficacy and safety of fluticasone propionate hydrofluoroalkane inhalation aerosol in pre-school-age children with asthma: a randomized, double-blind, placebo-controlled study. J Pediatr 2006;149:663–70.
    OpenUrlCrossRefPubMed
  55. 55.↵
    Skoner DP, Maspero J, Banerji D. Assessment of the long-term safety of inhaled ciclesonide on growth in children with asthma. Pediatrics 2008;121:e1–14.
    OpenUrlAbstract/FREE Full Text
  56. 56.↵
    Todd GR, Acerini CL, Ross-Russell R, et al. Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Arch Dis Child 2002;87:457–61.
    OpenUrlAbstract/FREE Full Text
  57. 57.↵
    Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. N Engl J Med 2000;343:1054–63.
    OpenUrlCrossRefPubMed
  58. 58.↵
    Pedersen S. Do inhaled corticosteroids inhibit growth in children?Am J Respir Crit Care Med 2001;164:521–35.
    OpenUrlCrossRefPubMed
  59. 59.↵
    Knorr B, Franchi LM, Bisgaard H, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 2001;108:E48.
    OpenUrlCrossRefPubMed
  60. 60.↵
    Straub DA, Moeller A, Minocchieri S, et al. The effect of montelukast on lung function and exhaled nitric oxide in infants with early childhood asthma. Eur Respir J 2005;25:289–94.
    OpenUrlAbstract/FREE Full Text
  61. 61.↵
    Garcia Garcia ML, Wahn U, Gilles L, et al. Montelukast, compared with fluticasone, for control of asthma among 6- to 14-year-old patients with mild asthma: the MOSAIC study. Pediatrics 2005;116:360–9.
    OpenUrlAbstract/FREE Full Text
  62. 62.↵
    Sorkness CA, Lemanske RF Jr, Mauger DT, et al. Long-term comparison of 3 controller regimens for mild–moderate persistent childhood asthma: the Pediatric Asthma Controller Trial. J Allergy Clin Immunol 2007;119:64–72.
    OpenUrlCrossRefPubMed
  63. 63.↵
    Szefler SJ, Phillips B, Martinez FD, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 2005;115:233–42.
    OpenUrlCrossRefPubMed
  64. 64.↵
    Bisgaard H, Le Roux P, Bjamer D, et al. Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma. Chest 2006;130:1733–43.
    OpenUrlCrossRefPubMed
  65. 65.↵
    Asthma in Canada: a landmark survey. Mississauga (ON): Glaxo Wellcome Inc.; 2000.
  66. 66.↵
    Bisgaard H. Effect of long-acting beta2 agonists on exacerbation rates of asthma in children. Pediatr Pulmonol 2003;36:391–8.
    OpenUrlCrossRefPubMed
  67. 67.↵
    Pohunek P, Kuna P, Jorup C, et al. Budesonide/formoterol improves lung function compared with budesonide alone in children with asthma. Pediatr Allergy Immunol 2006;17:458–65.
    OpenUrlCrossRefPubMed
  68. 68.↵
    Miraglia del GM, Piacentini GL, Capasso M, et al. Formoterol, montelukast, and budesonide in asthmatic children: effect on lung function and exhaled nitric oxide. Respir Med 2007;101:1809–13.
    OpenUrlCrossRefPubMed
  69. 69.↵
    Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001;108:E36.
    OpenUrlCrossRefPubMed
  70. 70.↵
    Chapman KR, Cartier A, Hebert J, et al. The role of omalizumab in the treatment of severe allergic asthma. Can Respir J 2006;(Suppl 13):1B–9B.
  71. 71.↵
    Chalut DS, Ducharme FM, Davis GM. The Preschool Respiratory Assessment Measure (PRAM): a responsive index of acute asthma severity. J Pediatr 2000; 137:762–8.
    OpenUrlCrossRefPubMed
  72. 72.↵
    Ducharme FM, Chalut D, Plotnick L et al. The pediatric respiratory assessment measure: a valid clinical score for assessing acute asthma severity from toddlers to teenagers. J Pediatr 2008;152:476–80.
    OpenUrlCrossRefPubMed
  73. 73.↵
    Canny GJ, Reisman J, Healy R, et al. Acute asthma: observations regarding the management of a pediatric emergency room. Pediatrics 1989;83:507–12.
    OpenUrlAbstract/FREE Full Text
  74. 74.↵
    American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis. Diagnosis and management of bronchiolitis. Pediatrics 2006;118: 1774–93.
    OpenUrlAbstract/FREE Full Text
  75. 75.↵
    Guthrie BD, Adler MD, Powell EC. End-tidal carbon dioxide measurements in children with acute asthma. Acad Emerg Med 2007;14:1135–40.
    OpenUrlCrossRefPubMed
  76. 76.↵
    Lindahl SG, Yates AP, Hatch DJ. Relationship between invasive and noninvasive measurements of gas exchange in anesthetized infants and children. Anesthesiology 1987;66:168–75.
    OpenUrlCrossRefPubMed
  77. 77.↵
    Castro-Rodriguez JA, Rodrigo GJ. β-Agonists through metered-dose inhaler with valved holding chamber versus nebulizer for acute exacerbation of wheezing or asthma in children under 5 years of age: a systematic review with meta-analysis. J Pediatr 2004;145:172–7.
    OpenUrlCrossRefPubMed
  78. 78.↵
    Mandelberg A, Tsehori S, Houri S, et al. Is nebulized aerosol treatment necessary in the pediatric emergency department?Chest 2000;117:1309–13.
    OpenUrlCrossRefPubMed
  79. 79.↵
    Delgado A, Chou KJ, Silver EJ, et al. Nebulizers vs metered-dose inhalers with spacers for bronchodilator therapy to treat wheezing in children aged 2 to 24 months in a pediatric emergency department. Arch Pediatr Adolesc Med 2003;157: 76–80.
    OpenUrlPubMed
  80. 80.↵
    Tal A, Golan H, Grauer N, et al. Deposition pattern of radiolabeled salbutamol inhaled from a metered-dose inhaler by means of a spacer with mask in young children with airway obstruction. J Pediatr 1996;128:479–84.
    OpenUrlCrossRefPubMed
  81. 81.↵
    Chua HL, Collis GG, Newbury AM, et al. The influence of age on aerosol deposition in children with cystic fibrosis. Eur Respir J 1994;7:2185–91.
    OpenUrlAbstract/FREE Full Text
  82. 82.↵
    Kerem E, Levison H, Schuh S, et al. Efficacy of albuterol administered by nebulizer versus spacer device in children with acute asthma. J Pediatr 1993;123:313–7.
    OpenUrlCrossRefPubMed
  83. 83.↵
    Wildhaber JH, Dore ND, Wilson JM, et al. Inhalation therapy in asthma: nebulizer or pressurized metered-dose inhaler with holding chamber? In vivo comparison of lung deposition in children. J Pediatr 1999;135:28–33.
    OpenUrlCrossRefPubMed
  84. 84.↵
    Schuh S, Parkin P, Rajan A, et al. High- versus low-dose, frequently administered, nebulized albuterol in children with severe, acute asthma. Pediatrics 1989;83:513–8.
    OpenUrlAbstract/FREE Full Text
  85. 85.↵
    Camargo CA Jr, Spooner CH, Rowe BH. Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database Syst Rev 2003;(4): CD001115.
  86. 86.↵
    Khine H, Fuchs SM, Saville AL. Continuous vs intermittent nebulized albuterol for emergency management of asthma. Acad Emerg Med 1996;3:1019–24.
    OpenUrlPubMed
  87. 87.↵
    Osmond MH, Klassen TP. Efficacy of ipratropium bromide in acute childhood asthma: a meta-analysis. Acad Emerg Med 1995;2:651–6.
    OpenUrlPubMed
  88. 88.↵
    Schuh S, Johnson DW, Callahan S, et al. Efficacy of frequent nebulized ipratropium bromide added to frequent high-dose albuterol therapy in severe childhood asthma. J Pediatr 1995;126:639–45.
    OpenUrlCrossRefPubMed
  89. 89.↵
    Qureshi F, Pestian J, Davis P, et al. Effect of nebulized ipratropium on the hospitalization rates of children with asthma. N Engl J Med 1998;339:1030–5.
    OpenUrlCrossRefPubMed
  90. 90.↵
    Chakraborti A, Lodha R, Pandey RM, et al. Randomized controlled trial of ipratropium bromide and salbutamol versus salbutamol alone in children with acute exacerbation of asthma. Indian J Pediatr 2006;73:979–83.
    OpenUrlCrossRefPubMed
  91. 91.↵
    Rowe BH, Spooner C, Ducharme FM, et al. Early emergency department treatment of acute asthma with systemic corticosteroids. Cochrane Database Syst Rev 2001;(1):CD002178.
  92. 92.↵
    O’Driscoll BR, Kalra S, Wilson M, et al. Double-blind trial of steroid tapering in acute asthma. Lancet 1993;341:324–7.
    OpenUrlCrossRefPubMed
  93. 93.↵
    Qureshi F, Zaritsky A, Poirier MP. Comparative efficacy of oral dexamethasone versus oral prednisone in acute pediatric asthma. J Pediatr 2001;139:20–6.
    OpenUrlCrossRefPubMed
  94. 94.↵
    Altamimi S, Robertson G, Jastaniah W, et al. Single-dose oral dexamethasone in the emergency management of children with exacerbations of mild to moderate asthma. Pediatr Emerg Care 2006;22:786–93.
    OpenUrlCrossRefPubMed
  95. 95.↵
    Schuh S, Dick PT, Stephens D, et al. High-dose inhaled fluticasone does not replace oral prednisolone in children with mild to moderate acute asthma. Pediatrics 2006;118:644–50.
    OpenUrlAbstract/FREE Full Text
  96. 96.↵
    Schuh S, Reisman J, Alshehri M, et al. A comparison of inhaled fluticasone and oral prednisone for children with severe acute asthma. N Engl J Med 2000;343: 689–94.
    OpenUrlCrossRefPubMed
  97. 97.↵
    Edmonds ML, Camargo CA Jr, Pollack CV Jr, et al. Early use of inhaled corticosteroids in the emergency department treatment of acute asthma. Cochrane Database Syst Rev 2003;(3):CD002308.
  98. 98.↵
    Rolla G, Bucca C, Caria E, et al. Acute effect of intravenous magnesium sulfate on airway obstruction of asthmatic patients. Ann Allergy 1988;61:388–91.
    OpenUrlPubMed
  99. 99.↵
    Cairns CB, Kraft M. Magnesium attenuates the neutrophil respiratory burst in adult asthmatic patients. Acad Emerg Med 1996;3:1093–7.
    OpenUrlPubMed
  100. 100.↵
    Ciarallo L, Sauer AH, Shannon MW. Intravenous magnesium therapy for moderate to severe pediatric asthma: results of a randomized, placebo-controlled trial. J Pediatr 1996;129:809–14.
    OpenUrlCrossRefPubMed
  101. 101.↵
    Silverman RA, Osborn H, Runge J, et al. IV magnesium sulfate in the treatment of acute severe asthma: a multicenter randomized controlled trial. Chest 2002;122: 489–97.
    OpenUrlCrossRefPubMed
  102. 102.↵
    Cheuk DK, Chau TC, Lee SL. A meta-analysis on intravenous magnesium sulphate for treating acute asthma. Arch Dis Child 2005;90:74–7.
    OpenUrlAbstract/FREE Full Text
  103. 103.↵
    Blitz M, Blitz S, Beasely R, et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database Syst Rev 2005;(4):CD003898.
  104. 104.↵
    Rodrigo G, Pollack C, Rodrigo C, et al. Heliox for nonintubated acute asthma patients. Cochrane Database Syst Rev 2006;(4):CD002884.
  105. 105.↵
    Kim IK, Saville AL, Sikes KL, et al. Heliox-driven albuterol nebulization for asthma exacerbations: an overview. Respir Care 2006;51:613–8.
    OpenUrlPubMed
  106. 106.↵
    Kim IK, Phrampus E, Venkataraman S, et al. Helium/oxygen-driven albuterol nebulization in the treatment of children with moderate to severe asthma exacerbations: a randomized, controlled trial. Pediatrics 2005;116:1127–33.
    OpenUrlAbstract/FREE Full Text
  107. 107.↵
    Zemek RL, Bhogal SK, Ducharme FM. Systematic review of randomized controlled trials examining written action plans in children: What is the plan?Arch Pediatr Adolesc Med 2008;162:157–63.
    OpenUrlCrossRefPubMed
  108. 108.↵
    Teach SJ, Crain EF, Quint DM, et al. Improved asthma outcomes in a high-morbidity pediatric population: results of an emergency department-based randomized clinical trial. Arch Pediatr Adolesc Med 2006;160:535–41.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Canadian Medical Association Journal: 182 (4)
CMAJ
Vol. 182, Issue 4
9 Mar 2010

Article tools

Respond to this article
Print
Download PDF
Article Alerts
Email Article
Citation Tools
Achieving control of asthma in preschoolers
Thomas Kovesi, Suzanne Schuh, Sheldon Spier, Denis Bérubé, Stuart Carr, Wade Watson, R. Andrew McIvor
CMAJ Mar 2010, 182 (4) E172-E183; DOI: 10.1503/cmaj.071638
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo

Jump to section

Collections

 

View Latest Classified Ads